Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 31/05/2024
• Auteurs : Rita BentahilaKarim BensalahNicolas Benziane-OuaritiniPhilippe BarthelemyNathalie Rioux-LeclercJean-Michel CorreasSarah BelhommePierre BigotPaul Sargos
• Organismes : Institut Bergonié [Bordeaux] Service d'urologie [Rennes] = Urology [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Institut de recherche en santé, environnement et travail Institut Bergonié [Bordeaux] Service d'urologie [Rennes] = Urology [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Institut Bergonié [Bordeaux]
• Publié dans The French Journal of Urology le 29/03/2024

---

Résumé : Introduction - The incidence of localized renal cell carcinoma (RCC) is on the rise among individuals aged 70 and older. While the gold standard for treatment remains surgical resection, some elderly and frail patients with comorbidities are not eligible for this procedure. In selected cases, percutaneous thermal ablation, such as cryotherapy, microwave and radiofrequency, offers less invasive options. General anesthesia is sometimes necessary for such treatments, but most of the procedures can be conducted using mild or deep conscious sedation. This approach is preferably recommended for small cT1a tumors situated at a distance from the renal hilum and/or ureter. Active surveillance remains an alternative in the case of small low grade RCC although it may induce anxiety in certain patients. Recent research has highlighted the potentials of stereotactic ablative body radiotherapy (SABR) as a noninvasive, well-tolerated, and effective treatment for small renal tumors. This narrative review aims to explore recent advances in SABR for localized RCC, including appropriate patient selection, treatment modalities and administration, as well as efficacy and tolerance assessment. Material and methods - We conducted a literature review using the terms [kidney cancer], [renal cell carcinoma], [stereotactic radiotherapy], [SBRT], and [SABR] in the Medline, PubMed, and Embase databases, focusing on prospective and relevant retrospective studies published in English. Results - Studies report local control rates ranging from 70% to 100% with SABR, highlighting its efficacy in treating RCC. The decline in glomerular filtration rate (GFR) is approximately -5 to -17mL/min over the years following SABR. Common toxicities are rare, primarily CTCAE grade 1, include fatigue, nausea, chest or back pain, diarrhea, or gastritis. Conclusion - Stereotactic ablative body radiotherapy (SABR) may be considered as a viable option for patients with localized RCC who are not suitable candidates for surgery with a high local control rate and a favorable safety profile. This approach should be discussed in a multidisciplinary meeting and results from ongoing clinical trials are awaited.

---

Fichiers liés : Bentahila et al. - 2024 - Stereotactic Body Radiation Therapy for Primary Re.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 31/05/2024
• Auteurs : Camille GondranPierre-Yves DumasEmilie BérardAudrey BidetEric DelabesseSuzanne TavitianThibaut LeguayFrançoise HuguetCécile BorelEdouard ForcadeFrançois VergezJean-Philippe VialJean Baptiste RieuNicolas LechevalierIsabelle LuquetAlban CanaliEmilie KleinAudrey SarryAnne-Charlotte de GrandeArnaud PigneuxChristian RécherLaetitia LargeaudSarah Bertoli
• Organismes : Centre Hospitalier Universitaire de Toulouse Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Bordeaux Biothérapies des maladies génétiques et cancers Centre Hospitalier Universitaire de Toulouse Equipe AGING (CERPOP) Centre Hospitalier Universitaire de Bordeaux Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Université de Bordeaux Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Centre Hospitalier Universitaire de Bordeaux Université de Bordeaux Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Université Toulouse III - Paul Sabatier Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Université Toulouse III - Paul Sabatier Institut Universitaire du Cancer de Toulouse - Oncopole Centre Hospitalier Universitaire de Toulouse Université Toulouse III - Paul Sabatier
• Publié dans Blood Cancer Journal le 02/11/2020

---

Résumé : Abstract Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/ BCR::ABL1 , a distinct entity within the group of AML with defining genetic abnormalities, belong to the adverse-risk group of the 2022 ELN classification. However, there is little data on outcome since the era of tyrosine kinase inhibitors. Among 5819 AML cases included in the DATAML registry, 20 patients with de novo BCR::ABL1 + AML (0.3%) were identified. Eighteen patients treated with standard induction chemotherapy were analyzed in this study. Imatinib was added to chemotherapy in 16 patients. The female-to-male ratio was 1.25 and median age was 54 years. The t(9;22) translocation was the sole chromosomal abnormality in 12 patients. Main gene mutations detected by NGS were ASXL1 , RUNX1 and NPM1 . Compared with patients with myeloid blast phase of chronic myeloid leukemia (CML-BP), de novo BCR::ABL1 + AML had higher WBC, fewer additional chromosomal abnormalities, lower CD36 or CD7 expression and no ABL1 mutations. Seventeen patients (94.4%) achieved complete remission (CR) or CR with incomplete hematologic recovery. Twelve patients were allografted in first remission. With a median follow-up of 6.3 years, the median OS was not reached and 2-year OS was 77% (95% CI: 50–91). Four out of five patients who were not transplanted did not relapse. Comparison of BCR::ABL1 + AML, CML-BP, 2017 ELN intermediate ( n = 643) and adverse-risk patients ( n = 863) showed that patients with BCR::ABL1 + AML had a significant better outcome than intermediate and adverse-risk patients. BCR::ABL1 + AML patients treated with imatinib and intensive chemotherapy should not be included in the adverse-risk group of current AML classifications.

---

Fichiers liés : s41408-024-01069-9.pdf

---

Source

---

• Type de publi. : Chapître d'ouvrage
• Date de publi. : 30/05/2024
• Auteurs : Renaud EscudiéYan RafrafiJ. FiguerasSébastien PommierPierre BuffièreClaire DumasJean-Philippe Delgenès
• Organismes : Laboratoire de Biotechnologie de l'Environnement [Narbonne] Toulouse Biotechnology Institute Déchets Eaux Environnement Pollutions Toulouse Biotechnology Institute Déchets Eaux Environnement Pollutions Symbiose : Ecosystèmes microbiens et bioprocédés d’épuration et de valorisation Toulouse Biotechnology Institute Laboratoire de Biotechnologie de l'Environnement [Narbonne]

---

Source

---

• Type de publi. :
• Date de publi. : 29/05/2024
• Auteurs : Jeanne AigoinBruno PayreJeanne Minvielle MonclaMélanie EscuderoDominique GoudounècheDaniel Ferri-AnguloPierre-François CalmonLaurence VayssePhilippe KémounLaurent MalaquinJulie Foncy
• Organismes : Service Techniques et Équipements Appliqués à la Microélectronique Service Instrumentation Conception Caractérisation Centre de Microscopie Électronique Appliquée à la Biologie Geroscience and rejuvenation research center Équipe Ingénierie pour les sciences du vivant Geroscience and rejuvenation research center Centre de Microscopie Électronique Appliquée à la Biologie Service Techniques et Équipements Appliqués à la Microélectronique Service Techniques et Équipements Appliqués à la Microélectronique Geroscience and rejuvenation research center Geroscience and rejuvenation research center Équipe Ingénierie pour les sciences du vivant Service Instrumentation Conception Caractérisation

---

Résumé :

---

Fichiers liés : Poster cargèse.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 26/05/2024
• Auteurs : Maxime BorretMarie BellioAlicia VauclardEmma LefrancaisPierre-Damien DenechaudAnne AbotClaude KnaufFrancois BriandThierry SulpiceLaurence PayrastrePhilippe ValetE. Guillou HervJean-Philippe PradereBernard PayrastreSonia Severin
• Organismes : Institut des Maladies Métaboliques et Casdiovasculaires Institut des Maladies Métaboliques et Casdiovasculaires Institut des Maladies Métaboliques et Casdiovasculaires Institut de pharmacologie et de biologie structurale Institut des Maladies Métaboliques et Casdiovasculaires Enterosys Enterosys Physiogenex Physiogenex ToxAlim Geroscience and rejuvenation research center ToxAlim Geroscience and rejuvenation research center Institut des Maladies Métaboliques et Casdiovasculaires Institut des Maladies Métaboliques et Casdiovasculaires

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 23/05/2024
• Auteurs : Sarah BenghanemNathalie KubisEtienne GayatAmbre LoiodiceEstelle Pruvost-RobieuxTarek SharsharArnaud FoucrierSamy FigueiredoViviane BouilleretEtienne de MontmollinFrançois BagateJean-Pascal LefaucheurBertrand GuidetEmmanuelle AppartisAlain CariouOlivier VarnetPaul Henri JostBruno MegarbaneVincent DegosLoic Le GuennecLionel NaccacheStephane LegrielFrance WoimantCharles GregoireDavid CortierIsabelle CrassardJean-François TimsitMikael MazighiRomain SonnevilleTiare AderEric BarréHélène BoutPerrine BoursinEric BodiguelDamien BressonOmar Ben Hadj SalemAlain CombesAnne ChrismentMagalie ColletJacque DuranteauSophie CrozierDaniel da SilvaAmexandre DemouleMaxens DecaveleEric DelpierreJean-Luc DiehlMartin DresFrédéric FaugerasMarie-Céline FournierTobias GaussCoralie GernezGuillaume GériDominique HurelMatthieu JammeLaurence JosseIgor JurcisinLionel KerhuelCatherine LamyFariza LamaraAymeric LancelotBertrand LapergueChristophe LencludMathilde LermuzeauxEric MagalhaesEric MariotteIsabelle MalissinAlain MaldjianNathalie MarinJérôme MartinThibault MartinezArmand Mekontso DessapMehran MonchiGiulia NaimHervé OutinDavid OsmanGregory PapinPierre PasquierClaire PichereauMatthieu PissotKeyvan RazaziDanielle ReuterChristian RichardStephane RucklyDamien RouxCaroline SchimpfQuentin StaiqulyJérôme ServanSebastien TanakaLaurie-Anne ThionKarim ToumertWidad TrakiMarc TranPhilippe VasselBernard ViguéDaniel ZafimahazoJonathan Zarka
• Organismes : Institut de psychiatrie et neurosciences de Paris Hôpital Lariboisière-Fernand-Widal [APHP] Optimisation thérapeutique en Neuropsychopharmacologie Département d’Anesthésie-Réanimation-SMUR [Hôpital Lariboisière] GHU AP-HP Nord - Université Paris Cité Marqueurs cardiovasculaires en situation de stress ICUREsearch Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Institut de psychiatrie et neurosciences de Paris Institut de psychiatrie et neurosciences de Paris Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Centre Hospitalier Sainte Anne [Paris] Hôpital Beaujon [AP-HP] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Université Paris-Saclay Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Institut Mondor de Recherche Biomédicale Groupe de recherche clinique CARMAS (Cardiovascular and Respiratory Manifestations of Acute lung injury and Sepsis) Hôpital Henri Mondor Excitabilité nerveuse et thérapeutique Hôpital Henri Mondor CHU Saint-Antoine [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Hôpital Cochin [AP-HP] Optimisation thérapeutique en Neuropsychopharmacologie Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière] CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut de neurosciences translationnelles de Paris Centre Hospitalier Universitaire [CHU Grenoble] Université Grenoble Alpes
• Publié dans Critical Care le 31/10/2020

---

Résumé : Abstract Introduction Prognostication of outcome in severe stroke patients necessitating invasive mechanical ventilation poses significant challenges. The objective of this study was to assess the prognostic significance and prevalence of early electroencephalogram (EEG) abnormalities in adult stroke patients receiving mechanical ventilation. Methods This study is a pre-planned ancillary investigation within the prospective multicenter SPICE cohort study (2017–2019), conducted in 33 intensive care units (ICUs) in the Paris area, France. We included adult stroke patients requiring invasive mechanical ventilation, who underwent at least one intermittent EEG examination during their ICU stay. The primary endpoint was the functional neurological outcome at one year, determined using the modified Rankin scale (mRS), and dichotomized as unfavorable (mRS 4–6, indicating severe disability or death) or favorable (mRS 0–3). Multivariable regression analyses were employed to identify EEG abnormalities associated with functional outcomes. Results Of the 364 patients enrolled in the SPICE study, 153 patients (49 ischemic strokes, 52 intracranial hemorrhages, and 52 subarachnoid hemorrhages) underwent at least one EEG at a median time of 4 (interquartile range 2–7) days post-stroke. Rates of diffuse slowing (70% vs. 63%, p = 0.37), focal slowing (38% vs. 32%, p = 0.15), periodic discharges (2.3% vs. 3.7%, p = 0.9), and electrographic seizures (4.5% vs. 3.7%, p = 0.4) were comparable between patients with unfavorable and favorable outcomes. Following adjustment for potential confounders, an unreactive EEG background to auditory and pain stimulations (OR 6.02, 95% CI 2.27–15.99) was independently associated with unfavorable outcomes. An unreactive EEG predicted unfavorable outcome with a specificity of 48% (95% CI 40–56), sensitivity of 79% (95% CI 72–85), and positive predictive value (PPV) of 74% (95% CI 67–81). Conversely, a benign EEG (defined as continuous and reactive background activity without seizure, periodic discharges, triphasic waves, or burst suppression) predicted favorable outcome with a specificity of 89% (95% CI 84–94), and a sensitivity of 37% (95% CI 30–45). Conclusion The absence of EEG reactivity independently predicts unfavorable outcomes at one year in severe stroke patients requiring mechanical ventilation in the ICU, although its prognostic value remains limited. Conversely, a benign EEG pattern was associated with a favorable outcome.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 23/05/2024
• Auteurs : Nazim SemmaniFrançois FournierJean-Pierre SucSéverine FauquetteMichel SérannePhilippe LeonideFrançois FournierJean Borgomano
• Organismes : Centre Européen de Recherche et d'Enseignement des Géosciences de l'Environnement IFP Energies nouvelles Centre Européen de Recherche et d'Enseignement des Géosciences de l'Environnement Institut des Sciences de la Terre de Paris Institut des Sciences de l'Evolution de Montpellier Géosciences Montpellier Centre Européen de Recherche et d'Enseignement des Géosciences de l'Environnement Centre Européen de Recherche et d'Enseignement des Géosciences de l'Environnement Centre Européen de Recherche et d'Enseignement des Géosciences de l'Environnement
• Publié dans Bulletin de la Société Géologique de France le 28/10/2020

---

Résumé : Based on detailed sedimentological analyses of cores, interpretation of well logs and a set of geochemical measurements performed on lacustrine sedimentary rocks, the palaeoenvironmental evolution and the sedimentary architecture of the Paleogene continental Vistrenque Basin (SE France) have been reconstructed. The analysis of sedimentary archives revealed three main stages of basin infill evolution: (1) a deep-lake basin (Priabonian-earliest Rupelian) whose sedimentation was dominated by terrigenous gravity-driven deposits during a period of high subsidence rate and strike-slip fault activity and under a prevailing humid climate; (2) an evaporative deep lake (early Rupelian) characterized by a drastic reduction in lake volume (forced-regression), terrigenous supplies and deposition of evaporites in disconnected sub-basins; (3) an overall long-term normal regressive stage (middle Rupelian to earliest Chattian) of lake infill characterized by an increase in terrigenous supplies and a vertical upward transition from deep-lake gravity-driven deposits to marginal lake and floodplain sedimentation. The onset of lake volume reduction and forced regression during the early Rupelian is associated with (1) the reworking of marginal lake carbonates into the deep lake areas, (2) the deposition of organic-rich sediments (TOC > 10%) coupled with sulphate-reduction processes in the deepest areas of the lake, (3) an important decrease in terrigenous supplies and (4) a long-term increase in δ 18 O of matrix-supported carbonates. This early Rupelian forced regression of the Vistrenque lacustrine system is interpreted to result from a regional decrease in precipitation in response to global cooling during the Eocene-Oligocene Transition (EOT). The final infill of the Vistrenque lake system (late Rupelian-early Chattian) and the onset of a floodplain occurred in more humid conditions during a stage of decreased activity of the Nîmes Fault, prior to or during an early stage of the Liguro-Provençal rifting.

---

Fichiers liés : ContinentalDepositionalRecord.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 22/05/2024
• Auteurs : Pierre BergéMari ChaikovskaiaJean-Philippe Lucien GayonAlain Quilliot
• Organismes : Laboratoire d'Informatique, de Modélisation et d'Optimisation des Systèmes Laboratoire des Sciences du Numérique de Nantes Laboratoire d'Informatique, de Modélisation et d'Optimisation des Systèmes Laboratoire d'Informatique, de Modélisation et d'Optimisation des Systèmes

---

Résumé : We consider a scheduling problem with reconfigurable resources. Several types of jobs have to be processed by a set of identical resources (e.g. robots, workers, processors) over a discrete time horizon. In each time period, teams of resources must be formed to process jobs. During a given time period, a team handles one type of job and the number of jobs that can be processed depends on the team size. A resource which is used to perform some job type in a given period may be employed for another job type in the next period. The objective is to determine the minimum number of resources needed to meet a given demand for each job type. We provide a polynomial-time 4/3-approximation algorithm for this strongly NP-hard problem.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 22/05/2024
• Auteurs : Jérome HadjadjYann NguyenDalila MouloudjRim BourguibaMaël HeibligHassina AlouiChloe McavoyValentin LacombeSamuel ArdoisCorrado CampochiaroAlexandre MariaCyrille CoustalThibault ComontEstibaliz LazaroFrancois LifermannGuillaume Le GuennoHervé LobbesVincent GrobostRoderau OuthJulien CampagneAnais Dor-EtienneAlice GarnierYvan JamillouxAntoine DossierMaxime SamsonSylvain AudiaBarbara NicolasAlexis MathianBaptiste de MalepradeBenjamin de Sainte-MarieBenoit FaucherJean-David BouazizJonathan BronerCyril DumainCarole AntoineBenjamin CarpentierBrice CastelCeline Lartigau-RoussinÉtienne CrickxGeoffroy VolleDamien FayardPaul DeckerThomas MoulinetAnaël DumontAlexandre NguyenAchille AoubaJean-Philippe MartellosioMatthieu LevavasseurSebastien PuigrenierPascale AntoineJean-Thomas GiraudOlivier HermineCarole LacoutNihal MartisJean-Denis KaramFrancois ChassetLaurent ArnaudPaola MarianettiChristophe DelignyThibaud ChazalPascal Woaye-HuneMurielle Roux-SauvatAurore MeyerPierre SujobertPierre HirschNoemie AbisrorPierre FenauxOlivier KosmiderVincent JachietOlivier FainBenjamin TerrierArsène MékinianSophie Georgin-Lavialle
• Organismes : Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Immuno-Biologie des Lymphomes [CIRI] Centre Hospitalier Lyon Sud [CHU - HCL]
• Publié dans Annals of the Rheumatic Diseases le 26/10/2020

---

Résumé : Objectives Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease associated with somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutations. We aimed to evaluate the efficacy and safety of targeted therapies. Methods Multicentre retrospective study including patients with genetically proven VEXAS syndrome who had received at least one targeted therapy. Complete response (CR) was defined by a clinical remission, C-reactive protein (CRP) ≤10 mg/L and a ≤10 mg/day of prednisone-equivalent therapy, and partial response (PR) was defined by a clinical remission and a 50% reduction in CRP levels and glucocorticoid dose. Results 110 patients (median age 71 (68–79) years) who received 194 targeted therapies were included: 78 (40%) received Janus kinase (JAK) inhibitors (JAKi), 51 (26%) interleukin (IL)-6 inhibitors, 33 (17%) IL-1 inhibitors, 20 (10%) tumour necrosis factor (TNFα) blockers and 12 (6%) other targeted therapies. At 3 months, the overall response (CR and PR) rate was 24% with JAKi, 32% with IL-6 inhibitors, 9% with anti-IL-1 and 0% with TNFα blockers or other targeted therapies. At 6 months, the overall response rate was 30% with JAKi and 26% with IL-6 inhibitors. Survival without treatment discontinuation was significantly longer with JAKi than with the other targeted therapies. Among patients who discontinued treatment, causes were primary failure, secondary failure, serious adverse event or death in 43%, 14%, 19% and 19%, respectively, with JAKi and 46%, 11%, 31% and 9%, respectively, with IL-6 inhibitors. Conclusions This study shows the benefit of JAKi and IL-6 inhibitors, whereas other therapies have lower efficacy. These results need to be confirmed in prospective trials.

---

Source

---

• Type de publi. :
• Date de publi. : 21/05/2024
• Auteurs : Mrinalini-Lianne RaoOleksandr GlushonkovPierre CaronPascale TacnetPhilippe FrachetDominique BourgeoisJean-Philippe KlemanFabienne HansJoanna Timmins
• Organismes : Institut de biologie structurale Laboratoire de Bioimagerie et Pathologies Institut de biologie structurale Institut de biologie structurale Institut de biologie structurale Institut de biologie structurale Institut de biologie structurale Institut de biologie structurale Institut de biologie structurale

---

Résumé : DNA damage induced by conventional cytotoxic chemotherapies, activates various DNA repair mechanisms like the base excision repair (BER) pathway that contribute to chemoresistance. § The BER pathway eradicates small and non-helical distorting base lesions like oxidized bases. BER is initiated by a set of enzymes, known as DNA glycosylases that recognize and remove the damaged bases. For example, the bifunctional DNA glycosylase NTH1 preferentially targets the oxidized pyrimidine base, thymine glycol. § The aim of this project is to have a better understanding of the cellular distribution of NTH1, in relation with other BER proteins and chromatin markers, within the nucleus. The expected results could lead to the development of novel anticancer drugs, used to overcome chemoresistance.

---

Fichiers liés : MRAO 3R MR.pdf

---

Source